Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors

International Journal of Cancer

Volumn 118, Issue 2, 2006, Pages 396-404

  Shaik, Madhu Sudhan ^a   Chatterjee, Abhijit ^a   Jackson, Tanise ^a   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

A549; COX 2; PPAR ; PGE2

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOPLASMIC PHOSPHOLIPASE A2; DOCETAXEL; MICROSOMAL PROSTAGLANDIN E SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TUMOR LEVEL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG INTERACTIONS; FEMALE; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MICE; MICE, NUDE; PYRAZOLES; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 28844449149     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21325     Document Type: Article

References (53)

1. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TLM, Piazza G, Klein-Szanto AJP, Pamukcu R, Alila H, Baunn PA Jr, et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479-8.
2. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-84.
3. Hida T, Kozaki K, Ito H, Miyaishi O, Tatematsu Y, Suzuki T, Matsuo K, Sugiura T, Ogawa M, Takahasi T, Takahashi T. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522 and conventional anticancer drugs. Clin Cancer Res 2002;8:2443-7.
4. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
5. Williams CS, Watson AJM, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-51.
6. Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, Burton J. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 2001;7:3178-85.
7. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxgenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-5.
8. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2 negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-33.
9. Gadgeel SM, Thatai L, Kraut M, Wozniak A, Worden F, Ward D, Belzer K, Hodges C, Kalemkerian GP. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Abstract 2749. ASCO, 2003.
10. Shehadeh NJ, Kalemkerian GP, Wozniak A, Kruat M, Belzer K, Ward D, Hodges C, Gadgeel SM, Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly (?70 yrs) or PS2 patients with advanced non-small cell lung cancer (NSCLC). Abstract 2758. ASCO, 2003.
11. Nugent FW, Graziano S, Levitan N, Collea R, Gajra A, Mertens WC, O'Connell C, Sirard J, Marshall J, McCann J. Docetaxel and COX-2 inhibition with celecoxib in relapsed/refractory non-small cell lung cancer (NSCLC): promising progression-free survival in a phase II study. Abstract 2697. ASCO, 2003.
12. 2 in human head and neck xenograft tumors. Cancer Res 2002;62:6706-11.
13. Blaine SA, Wick M, Dessev C, Nemenoff RA. Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun. J Biol Chem 2001;276:42737-43.
14. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson P-J, Dannenberg AJ, Subbaramaiah K. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001;7:2669-74.
15. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 2003;9:1885-97.
16. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004;64:1369-76.
17. Haynes A, Shaik MS, Chatterjee A, Singh M. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in non-small cell lung cancer cell line. Pharmacol Res 2003;20:1485-95.
18. Shaik MS, Chatterjee A, Singh M. Effect of a selective cyclooxygenase (COX)-2 inhibitor, nimesulide on the growth of lung tumors and their expression of COX-2 and peroxisome proliferator-activated receptor-γ. Clin Cancer Res 2004;10:1521-9.
19. Haynes A, Shaik MS, Chatterjee A, Singh M. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharmacol Res 2005;22:427-39.
20. 2 in human breast cancer and metastasis. Int J Cancer 2003;103:84-90.
21. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann N Y Acad Sci 2001;952:109-15.
22. Subongkot S, Frame D, Leslie W, Drajer D. Selective cyclooxygenase-2 inhibition: A target in cancer prevention and treatment. Pharmacotherapy 2003;23:9-28.
23. Wolf H, Saukkonen K, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
24. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahasi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
25. Achiwa H, Yatabe Y, Hida T, Kuroish T, Kozaki K-I, Nakamura T, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
26. Hida T, Kozaki KI, Muramatusu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6:2006-11.
27. Teicher BA, Korbut TT, Menon K, Holden SA, Ara G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 1994;33:515-22.
28. Moore RJ, Zwelfi BS, Heuvelman DM, Leahy KM, Edwards DA, Woerner BM, Ornberg RL, Seibert K, Koki AT, Masferrer JL. Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU. Proc Am Assoc Cancer Res 2000;41:409.
29. Nakata E, Mason KA, Hunter N, Husain A, Raju U, Liao Z, Ang KK, Milas L. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 2004;58:369-75.
30. 2, a survival factor for tumor and associated vasculature. Cancer Res 2004;64:279-85.
31. Dykes DJ, Bissery MC, Harrison SD Jr, Waud WR. Response of human tumor xenografts in athymic nude mice to docetaxel (RP56976, Taxotere). Invest New Drugs 1995;13:1-11.
32. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji L. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 2001;7:2887-97.
33. Cassidy PB, Moos PJ, Kelly RC, Fitzpatrick FA. Cyclooxygenase-2 induction by paclitaxel, docetaxel and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin Cancer Res 2002;8:846-55.
34. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. J Biol Chem 2000;275:14838-45.
35. Merchan JR, Yayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by cox-2 inhibition. Int J Cancer 2005;113:490-8.
36. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer. J Clin Oncol 2003;21:2645-50.
37. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 1997;272:14501-4.
38. 2 formation. Int J Surg Investig 2000;1: 467-76.
39. 2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett 2003;547:75-9.
40. Badawi AF, Eldeen M, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor γ. Cancer Res 2004;64:1181-9.
41. Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, Sauk JJ. PPAR gamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer 2002;98:817-23.
42. Wick M, Hurteau G, Dessev C, Chan D, Geraci ME, Winni RA, Heasley LE, Nemenoff RA. Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal in-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002;62:1207-14.
43. 2. Biochem Biophys Res Commun 2001;283:750-55.
44. Gallo C, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Masini E. Cycloxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
45. Eibl G, Bruemmer D, Okada Y, Duffy JP, Law RE, Reber HA, Hines OJ. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2 expressing human pancreatic cancer cells. Biochem Biophys Res Commun 2003;306:887-97.
46. Kim KY, Lee JW, Ahn BW, Ryu PD, Nam MJ. Loss of endogenous TGF-β effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF. Hepatol Res 2003;26: 302-10.
47. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003;9:1566-72.
48. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-31.
49. Corcoran CA, He Q, Huang Y, Sheikh MS. Cycloxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 2005;24:1634-40.
50. Yu HG, Huang JA, Yang YN, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells. Regul Pept 2003;114:101-107.
51. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anti-Cane Agents 2003;3:291-306
52. Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Filipits M. Expression of cell cycle regulatory proteins in breast cancer carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 2003;78:97-103.
53. Avramis VI, Nandy P, Kwock R, Solorzano MM, Mukherjee SK, Dannenberg P, Cohen LJ. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res 1998;18:2327-38.